Paciraa (PCRX) October Exparel Data Suggests Q4 at Risk - BMO Capital
- Donald Trump Sworn in as 45th U.S. President
- Wall Street ends higher as Trump becomes president
- Walgreens Boots Alliance (WBA) Said to Face Antitrust Concern for Rite Aid (RAD) Fix - Bloomberg
- Bristol-Myers Squibb (BMY) Says It Won't Pursue Accelerated U.S. Regulatory Pathway for Opdivo Plus Yervoy in Lung Cancer
- Apple (AAPL) Sues Qualcomm (QCOM) Over Patent Royalties in Antitrust Case - Bloomberg
Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.
BMO Capital analyst Gary Nachman weighed in on Pacira Pharmaceuticals (NASDAQ: PCRX) after Symphony data were released today and October Exparel sales were $20.2mn, down 12% Y/Y and down 9% M/M. On a sales per selling day basis, Exparel declined 8% Y/Y and 5% M/M. PCRX recently reduced Exparel sales guidance to $263-268mn from $270-280mn along with 3Q results (we're at $263mn).
The October Exparel sales indicate meaningful growth is required for the remainder of 4Q to achieve the guidance. "We believe October is not a great start to 4Q and see a potential challenge in PCRX achieving even the low end of its guidance range," the analyst said.
The firm maintained a Market Perform rating and price target of $35.00
Shares of Pacira Pharmaceuticals closed at $34.35 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- TransDigm (TDG) Valeant Comparison 'Nothing New', Tweet Risk Low and Would Use Weakness to Buy - Credit Suisse
- UPDATE: Seaport Global Securities Starts GCP Applied Technologies (GCP) at Buy
- Generics File Against New Teva Pharma (TEVA) Copaxone 40MG Patent - Evercore ISI
Create E-mail Alert Related CategoriesAnalyst Comments, FDA, Trader Talk
Related EntitiesBMO Capital
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!